BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A, Rosso R, Zuber M, Muraro MG, Amicarella F, Cremonesi E, Heberer M, Iezzi G, Lugli A, Terracciano L, Sconocchia G, Oertli D, Spagnoli GC, Tornillo L. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013;49:2233-42. [PMID: 23478000 DOI: 10.1016/j.ejca.2013.02.015] [Cited by in Crossref: 246] [Cited by in F6Publishing: 267] [Article Influence: 27.3] [Reference Citation Analysis]
Number Citing Articles
1 Guo W, Wang P, Li N, Shao F, Zhang H, Yang Z, Li R, Gao Y, He J. Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis. Oncotarget 2018;9:13920-33. [PMID: 29568405 DOI: 10.18632/oncotarget.23810] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
2 De Meulenaere A, Vermassen T, Aspeslagh S, Huvenne W, Van Dorpe J, Ferdinande L, Rottey S. Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck. Oral Oncology 2017;70:34-42. [DOI: 10.1016/j.oraloncology.2017.05.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
3 Stasikowska-Kanicka O, Wągrowska-Danilewicz M, Danilewicz M. CD8+ and CD163+ infiltrating cells and PD-L1 immunoexpression in oral leukoplakia and oral carcinoma. APMIS 2018;126:732-8. [PMID: 30160018 DOI: 10.1111/apm.12881] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
4 AiErken N, Shi HJ, Zhou Y, Shao N, Zhang J, Shi Y, Yuan ZY, Lin Y. High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients. Int J Biol Sci 2017;13:1172-9. [PMID: 29104508 DOI: 10.7150/ijbs.20868] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
5 Jacobs J, Smits E, Lardon F, Pauwels P, Deschoolmeester V. Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res 2015;2015:158038. [PMID: 26605342 DOI: 10.1155/2015/158038] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
6 Wu JB, Sarmiento AL, Fiset PO, Lazaris A, Metrakos P, Petrillo S, Gao ZH. Histologic features and genomic alterations of primary colorectal adenocarcinoma predict growth patterns of liver metastasis. World J Gastroenterol 2019; 25(26): 3408-3425 [PMID: 31341365 DOI: 10.3748/wjg.v25.i26.3408] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
7 Du JW, Li GQ, Li YS, Qiu XG. Identification of prognostic biomarkers related to the tumor microenvironment in thyroid carcinoma. Sci Rep 2021;11:16239. [PMID: 34376710 DOI: 10.1038/s41598-021-90538-3] [Reference Citation Analysis]
8 Scognamiglio G, De Chiara A, Di Bonito M, Tatangelo F, Losito NS, Anniciello A, De Cecio R, D'Alterio C, Scala S, Cantile M, Botti G. Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types. Int J Mol Sci 2016;17:E790. [PMID: 27213372 DOI: 10.3390/ijms17050790] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
9 Erdogdu IH. MHC Class 1 and PDL-1 Status of Primary Tumor and Lymph Node Metastatic Tumor Tissue in Gastric Cancers. Gastroenterol Res Pract 2019;2019:4785098. [PMID: 30881447 DOI: 10.1155/2019/4785098] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
10 Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget 2017;8:91779-94. [PMID: 29207684 DOI: 10.18632/oncotarget.21586] [Cited by in Crossref: 164] [Cited by in F6Publishing: 156] [Article Influence: 32.8] [Reference Citation Analysis]
11 Kajihara M, Takakura K, Kanai T, Ito Z, Saito K, Takami S, Shimodaira S, Okamoto M, Ohkusa T, Koido S. Dendritic cell-based cancer immunotherapy for colorectal cancer. World J Gastroenterol 2016; 22(17): 4275-4286 [PMID: 27158196 DOI: 10.3748/wjg.v22.i17.4275] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
12 Rivera-Colon G, Chen H, Molberg K, Niu S, Strickland AL, Castrillon DH, Carrick K, Gwin K, Lea J, Zheng W, Lucas E. PD-L1 Expression in Endocervical Adenocarcinoma: Correlation With Patterns of Tumor Invasion, CD8+ Tumor-infiltrating Lymphocytes, and Clinical Outcomes. Am J Surg Pathol 2021;45:742-52. [PMID: 33298732 DOI: 10.1097/PAS.0000000000001633] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Shen Z, Gu L, Mao D, Chen M, Jin R. Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a systematic review and meta-analysis. World J Surg Oncol. 2019;17:4. [PMID: 30609938 DOI: 10.1186/s12957-018-1544-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
14 Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016;9:5023-5039. [PMID: 27574444 DOI: 10.2147/ott.s105862] [Cited by in Crossref: 297] [Cited by in F6Publishing: 192] [Article Influence: 49.5] [Reference Citation Analysis]
15 Liu B, Arakawa Y, Yokogawa R, Tokunaga S, Terada Y, Murata D, Matsui Y, Fujimoto KI, Fukui N, Tanji M, Mineharu Y, Minamiguchi S, Miyamoto S. PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes. PLoS One 2018;13:e0194594. [PMID: 29617441 DOI: 10.1371/journal.pone.0194594] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
16 Sorscher S, Resnick J, Goodman M. First Case Report of a Dramatic Radiographic Response to a Checkpoint Inhibitor in a Patient With Proficient Mismatch Repair Gene Expressing Metastatic Colorectal Cancer. JCO Precision Oncology 2017. [DOI: 10.1200/po.16.00005] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
17 Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS One 2014;9:e88557. [PMID: 24551119 DOI: 10.1371/journal.pone.0088557] [Cited by in Crossref: 141] [Cited by in F6Publishing: 134] [Article Influence: 17.6] [Reference Citation Analysis]
18 Liu S, Kong P, Wang X, Yang L, Jiang C, He W, Quan Q, Huang J, Xie Q, Xia X, Zhang B, Xia L. Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer. Oncol Lett 2019;17:2335-43. [PMID: 30675299 DOI: 10.3892/ol.2018.9826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Watanabe T, Okuda K, Murase T, Moriyama S, Haneda H, Kawano O, Yokota K, Sakane T, Oda R, Inagaki H, Nakanishi R. Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma. Oncotarget 2018;9:20769-80. [PMID: 29755688 DOI: 10.18632/oncotarget.25100] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
20 Rimm D, Schalper K, Pusztai L. Unvalidated antibodies and misleading results. Breast Cancer Res Treat. 2014;147:457-458. [PMID: 25086631 DOI: 10.1007/s10549-014-3061-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
21 Lang-Schwarz C, Melcher B, Hartmann A, Bertz S, Dregelies T, Lang-Schwarz K, Vieth M, Sterlacci W. Programmed death ligand 1 (PD-L1) in colon cancer and its interaction with budding and tumor-infiltrating lymphocytes (TILs) as tumor-host antagonists. Int J Colorectal Dis 2021. [PMID: 34170390 DOI: 10.1007/s00384-021-03985-9] [Reference Citation Analysis]
22 Messeha SS, Zarmouh NO, Soliman KFA. Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer. Nutrients 2021;13:1718. [PMID: 34069461 DOI: 10.3390/nu13051718] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Santarpia M, Karachaliou N. Tumor immune microenvironment characterization and response to anti-PD-1 therapy. Cancer Biol Med 2015;12:74-8. [PMID: 26175922 DOI: 10.7497/j.issn.2095-3941.2015.0022] [Cited by in F6Publishing: 32] [Reference Citation Analysis]
24 Kim WY, Jung HY, Nam SJ, Kim TM, Heo DS, Kim C, Jeon YK. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis. Virchows Arch 2016;469:581-90. [DOI: 10.1007/s00428-016-2011-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
25 Li HJ, Wang YL, Ming L, Guo XQ, Li YL, Wang JC, Zhang YQ, Cheng L. Development of a prognostic model based on an immunogenomic landscape analysis of colorectal cancer. Future Oncol 2021;17:301-13. [PMID: 32996773 DOI: 10.2217/fon-2020-0022] [Reference Citation Analysis]
26 Bedekovics J, Beke L, Mokanszki A, Szilagyi S, Mehes G. Programmed Death-ligand 1 (PD-L1) Expression in Thymic Epithelial Tumors. Appl Immunohistochem Mol Morphol 2020;28:1-9. [PMID: 30499814 DOI: 10.1097/PAI.0000000000000699] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
27 Kudo M. Pembrolizumab for the Treatment of Hepatocellular Carcinoma. Liver Cancer 2019;8:143-54. [PMID: 31192152 DOI: 10.1159/000500143] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
28 El Jabbour T, Ross JS, Sheehan CE, Affolter KE, Geiersbach KB, Boguniewicz A, Ainechi S, Bronner MP, Jones DM, Lee H. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry. J Clin Pathol 2018;71:46-51. [PMID: 28667193 DOI: 10.1136/jclinpath-2017-204525] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
29 Zhang W, Pang Q, Zhang X, Yan C, Wang Q, Yang J, Yu S, Liu X, Pan Y, Yuan Z, Wang P, Xiao Z. Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor. Cancer Sci 2017;108:590-7. [PMID: 28192623 DOI: 10.1111/cas.13197] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
30 Shao L, Peng Q, Du K, He J, Dong Y, Lin X, Li J, Wu J. Tumor cell PD-L1 predicts poor local control for rectal cancer patients following neoadjuvant radiotherapy. Cancer Manag Res 2017;9:249-58. [PMID: 28721097 DOI: 10.2147/CMAR.S139889] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
31 Fuertes Marraco SA, Neubert NJ, Verdeil G, Speiser DE. Inhibitory Receptors Beyond T Cell Exhaustion. Front Immunol. 2015;6:310. [PMID: 26167163 DOI: 10.3389/fimmu.2015.00310] [Cited by in Crossref: 122] [Cited by in F6Publishing: 115] [Article Influence: 17.4] [Reference Citation Analysis]
32 Oliveira-Costa JP, de Carvalho AF, da Silveira da GG, Amaya P, Wu Y, Park KJ, Gigliola MP, Lustberg M, Buim ME, Ferreira EN, Kowalski LP, Chalmers JJ, Soares FA, Carraro DM, Ribeiro-Silva A. Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells. Oncotarget 2015;6:20902-20. [PMID: 26041877 DOI: 10.18632/oncotarget.3939] [Cited by in Crossref: 65] [Cited by in F6Publishing: 68] [Article Influence: 10.8] [Reference Citation Analysis]
33 Park SM, Youn JI. Role of myeloid-derived suppressor cells in immune checkpoint inhibitor therapy in cancer. Arch Pharm Res 2019;42:560-6. [PMID: 31147902 DOI: 10.1007/s12272-019-01165-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
34 Jomrich G, Silberhumer GR, Marian B, Beer A, Müllauer L. Programmed death-ligand 1 expression in rectal cancer. Eur Surg 2016;48:352-6. [PMID: 28058043 DOI: 10.1007/s10353-016-0447-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
35 Martinez-Ciarpaglini C, Oltra S, Roselló S, Roda D, Mongort C, Carrasco F, Gonzalez J, Santonja F, Tarazona N, Huerta M, Espí A, Ribas G, Ferrández A, Navarro S, Cervantes A. Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression. Mod Pathol 2019;32:306-13. [PMID: 30206410 DOI: 10.1038/s41379-018-0124-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
36 Sadraei NH, Sikora AG, Brizel DM. Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer. American Society of Clinical Oncology Educational Book 2016. [DOI: 10.1200/edbk_157801] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
37 Yang CY, Lin MW, Chang YL, Wu CT, Yang PC. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 2014;50:1361-9. [PMID: 24548766 DOI: 10.1016/j.ejca.2014.01.018] [Cited by in Crossref: 194] [Cited by in F6Publishing: 217] [Article Influence: 24.3] [Reference Citation Analysis]
38 Watson HA, Wehenkel S, Matthews J, Ager A. SHP-1: the next checkpoint target for cancer immunotherapy? Biochem Soc Trans 2016;44:356-62. [PMID: 27068940 DOI: 10.1042/BST20150251] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
39 Miyoshi H, Kiyasu J, Kato T, Yoshida N, Shimono J, Yokoyama S, Taniguchi H, Sasaki Y, Kurita D, Kawamoto K, Kato K, Imaizumi Y, Seto M, Ohshima K. PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma. Blood 2016;128:1374-81. [PMID: 27418641 DOI: 10.1182/blood-2016-02-698936] [Cited by in Crossref: 83] [Cited by in F6Publishing: 78] [Article Influence: 13.8] [Reference Citation Analysis]
40 Chen K, Zhu Z, Zhang N, Cheng G, Zhang F, Jin J, Wu J, Ying L, Mao W, Su D. Tumor-Infiltrating CD4+ Lymphocytes Predict a Favorable Survival in Patients with Operable Esophageal Squamous Cell Carcinoma. Med Sci Monit 2017;23:4619-32. [PMID: 28949934 DOI: 10.12659/msm.904154] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
41 Hsu J, Hsu C, Le P, Chen T, Chou W, Lin C, Yeh T. Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1. Journal of Surgical Research 2017;211:30-8. [DOI: 10.1016/j.jss.2016.11.058] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
42 Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW, West RB, Wakelee HA. Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol. 2015;10:500-508. [PMID: 25402569 DOI: 10.1097/jto.0000000000000429] [Cited by in Crossref: 74] [Cited by in F6Publishing: 40] [Article Influence: 12.3] [Reference Citation Analysis]
43 Ugai T, Zhao M, Shimizu T, Akimoto N, Shi S, Takashima Y, Zhong R, Lau MC, Haruki K, Arima K, Fujiyoshi K, Langworthy B, Masugi Y, da Silva A, Nosho K, Baba Y, Song M, Chan AT, Wang M, Meyerhardt JA, Giannakis M, Väyrynen JP, Nowak JA, Ogino S. Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma. Oncoimmunology 2021;10:1956173. [PMID: 34377593 DOI: 10.1080/2162402X.2021.1956173] [Reference Citation Analysis]
44 Emambux S, Tachon G, Junca A, Tougeron D. Results and challenges of immune checkpoint inhibitors in colorectal cancer. Expert Opinion on Biological Therapy 2018;18:561-73. [DOI: 10.1080/14712598.2018.1445222] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
45 He J, Huo L, Ma J, Zhao J, Bassett RL, Sun X, Ueno NT, Lim B, Gong Y. Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. Am J Clin Pathol 2018;149:253-61. [PMID: 29425258 DOI: 10.1093/ajcp/aqx162] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
46 Xiang X, Yu PC, Long D, Liao XL, Zhang S, You XM, Zhong JH, Li LQ. Prognostic value of PD -L1 expression in patients with primary solid tumors. Oncotarget 2018;9:5058-72. [PMID: 29435162 DOI: 10.18632/oncotarget.23580] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
47 Ishii H, Azuma K, Kawahara A, Yamada K, Imamura Y, Tokito T, Kinoshita T, Kage M, Hoshino T. Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer. Journal of Thoracic Oncology 2015;10:426-30. [DOI: 10.1097/jto.0000000000000414] [Cited by in Crossref: 91] [Cited by in F6Publishing: 72] [Article Influence: 13.0] [Reference Citation Analysis]
48 Wallace TJ, Qian J, Avital I, Bay C, Man YG, Wellman LL, Moskaluk C, Troyer D, Ramnani D, Stojadinovic A. Technical Feasibility of Tissue Microarray (TMA) Analysis of Tumor-Associated Immune Response in Prostate Cancer. J Cancer 2018;9:2191-202. [PMID: 29937939 DOI: 10.7150/jca.22846] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
49 Sagaert X, Vanstapel A, Verbeek S. Tumor Heterogeneity in Colorectal Cancer: What Do We Know So Far? Pathobiology 2018;85:72-84. [PMID: 29414818 DOI: 10.1159/000486721] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
50 Masugi Y, Nishihara R, Yang J, Mima K, da Silva A, Shi Y, Inamura K, Cao Y, Song M, Nowak JA, Liao X, Nosho K, Chan AT, Giannakis M, Bass AJ, Hodi FS, Freeman GJ, Rodig S, Fuchs CS, Qian ZR, Ogino S. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut 2017;66:1463-73. [PMID: 27196573 DOI: 10.1136/gutjnl-2016-311421] [Cited by in Crossref: 94] [Cited by in F6Publishing: 97] [Article Influence: 15.7] [Reference Citation Analysis]
51 Sznurkowski JJ, Żawrocki A, Sznurkowska K, Pęksa R, Biernat W. PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients. Oncotarget 2017;8:89903-12. [PMID: 29163797 DOI: 10.18632/oncotarget.20911] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
52 Ho Y, Chen YF, Wang LH, Hsu KY, Chin YT, Yang YSH, Wang SH, Chen YR, Shih YJ, Liu LF, Wang K, Whang-Peng J, Tang HY, Lin HY, Liu HL, Lin SJ. Inhibitory Effect of Anoectochilus formosanus Extract on Hyperglycemia-Related PD-L1 Expression and Cancer Proliferation. Front Pharmacol 2018;9:807. [PMID: 30116189 DOI: 10.3389/fphar.2018.00807] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
53 Jikuya R, Kishida T, Sakaguchi M, Yokose T, Yasui M, Hashizume A, Tatenuma T, Mizuno N, Muraoka K, Umemoto S, Kawai M, Yoshihara M, Nakamura Y, Miyagi Y, Sasada T. Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma. Cancer Immunol Immunother 2020;69:2041-51. [PMID: 32424467 DOI: 10.1007/s00262-020-02608-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Kollmann D, Schweiger T, Schwarz S, Ignatova D, Chang YT, Lewik G, Schoppmann SF, Hoetzenecker W, Klepetko W, Guenova E, Hoetzenecker K. PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer. Oncoimmunology 2017;6:e1331194. [PMID: 28932634 DOI: 10.1080/2162402X.2017.1331194] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
55 Muenst S, Schaerli AR, Gao F, Däster S, Trella E, Droeser RA, Muraro MG, Zajac P, Zanetti R, Gillanders WE, Weber WP, Soysal SD. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2014;146:15-24. [PMID: 24842267 DOI: 10.1007/s10549-014-2988-5] [Cited by in Crossref: 302] [Cited by in F6Publishing: 320] [Article Influence: 37.8] [Reference Citation Analysis]
56 Shi SJ, Wang LJ, Wang GD, Guo ZY, Wei M, Meng YL, Yang AG, Wen WH. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PLoS One. 2013;8:e76012. [PMID: 24124529 DOI: 10.1371/journal.pone.0076012] [Cited by in Crossref: 90] [Cited by in F6Publishing: 101] [Article Influence: 10.0] [Reference Citation Analysis]
57 Zhang X, Wu Q, Hu T, Gu C, Bi L, Wang Z. Laparoscopic versus conventional open surgery in T4 rectal cancer: A case-control study. J Minim Access Surg 2019;15:37-41. [PMID: 30416145 DOI: 10.4103/jmas.JMAS_67_18] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
58 Zhao X, May A, Lou E, Subramanian S. Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer. Transl Res 2018;196:62-70. [PMID: 29518351 DOI: 10.1016/j.trsl.2018.02.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Lim YJ, Koh J, Kim K, Chie EK, Kim S, Lee KB, Jang J, Kim SW, Oh D, Bang Y. Clinical Implications of Cytotoxic T Lymphocyte Antigen-4 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Extrahepatic Bile Duct Cancer Patients Undergoing Surgery Plus Adjuvant Chemoradiotherapy. Targ Oncol 2017;12:211-8. [DOI: 10.1007/s11523-016-0474-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
60 Wang Q, Liu F, Liu L. Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis. Medicine (Baltimore) 2017;96:e6369. [PMID: 28471952 DOI: 10.1097/MD.0000000000006369] [Cited by in Crossref: 99] [Cited by in F6Publishing: 69] [Article Influence: 19.8] [Reference Citation Analysis]
61 Atanackovic D, Luetkens T, Kröger N. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia 2014;28:993-1000. [DOI: 10.1038/leu.2013.310] [Cited by in Crossref: 68] [Cited by in F6Publishing: 74] [Article Influence: 7.6] [Reference Citation Analysis]
62 Brockhoff G, Seitz S, Weber F, Zeman F, Klinkhammer-Schalke M, Ortmann O, Wege AK. The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease. Oncotarget 2018;9:6201-12. [PMID: 29464065 DOI: 10.18632/oncotarget.23717] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
63 Sun WY, Lee YK, Koo JS. Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. J Transl Med 2016;14:173. [PMID: 27286842 DOI: 10.1186/s12967-016-0925-6] [Cited by in Crossref: 63] [Cited by in F6Publishing: 70] [Article Influence: 10.5] [Reference Citation Analysis]
64 Sconocchia G, Eppenberger-Castori S, Zlobec I, Karamitopoulou E, Arriga R, Coppola A, Caratelli S, Spagnoli GC, Lauro D, Lugli A, Han J, Iezzi G, Ferrone C, Ferlosio A, Tornillo L, Droeser R, Rossi P, Attanasio A, Ferrone S, Terracciano L. HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker. Neoplasia 2014;16:31-42. [PMID: 24563618 DOI: 10.1593/neo.131568] [Cited by in Crossref: 57] [Cited by in F6Publishing: 61] [Article Influence: 7.1] [Reference Citation Analysis]
65 Li Y, He M, Zhou Y, Yang C, Wei S, Bian X, Christopher O, Xie L. The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis. Front Pharmacol 2019;10:139. [PMID: 30873025 DOI: 10.3389/fphar.2019.00139] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 11.7] [Reference Citation Analysis]
66 Cacciotti C, Choi J, Alexandrescu S, Zimmerman MA, Cooney TM, Chordas C, Clymer J, Chi S, Yeo KK. Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience. J Neurooncol 2020;149:113-22. [PMID: 32627129 DOI: 10.1007/s11060-020-03578-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
67 Roussille P, Tachon G, Villalva C, Milin S, Frouin E, Godet J, Berger A, Emambux S, Petropoulos C, Wager M, Karayan-Tapon L, Tougeron D. Pathological and Molecular Characteristics of Colorectal Cancer with Brain Metastases. Cancers (Basel) 2018;10:E504. [PMID: 30544743 DOI: 10.3390/cancers10120504] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
68 Yokoyama S, Miyoshi H. Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma. J Thorac Dis 2020;12:7553-60. [PMID: 33447446 DOI: 10.21037/jtd-19-3703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 García-Díez I, Hernández-Ruiz E, Andrades E, Gimeno J, Ferrándiz-Pulido C, Yébenes M, García-Patos V, Pujol RM, Hernández-Muñoz I, Toll A. PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases. Am J Dermatopathol 2018;40:647-54. [PMID: 29742559 DOI: 10.1097/DAD.0000000000001164] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
70 Sun JM, Zhou W, Choi YL, Choi SJ, Kim SE, Wang Z, Dolled-Filhart M, Emancipator K, Wu D, Weiner R, Frisman D, Kim HK, Choi YS, Shim YM, Kim J. Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases. J Thorac Oncol 2016;11:1003-11. [PMID: 27103510 DOI: 10.1016/j.jtho.2016.04.007] [Cited by in Crossref: 94] [Cited by in F6Publishing: 101] [Article Influence: 15.7] [Reference Citation Analysis]
71 Ho HL, Chou TY, Yang SH, Jiang JK, Chen WS, Chao Y, Teng HW. PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1. J Cancer Res Clin Oncol 2019;145:1785-94. [PMID: 31129768 DOI: 10.1007/s00432-019-02942-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
72 Dislich B, Stein A, Seiler CA, Kröll D, Berezowska S, Zlobec I, Galvan J, Slotta-Huspenina J, Walch A, Langer R. Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: comparison between primary tumors and metastases. Cancer Immunol Immunother 2017;66:777-86. [PMID: 28289861 DOI: 10.1007/s00262-017-1982-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
73 Jiang D, Song Q, Wang H, Huang J, Wang H, Hou J, Li X, Xu Y, Sujie A, Zeng H, Tan L, Hou Y. Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma. Oncotarget 2017;8:8315-29. [PMID: 28039448 DOI: 10.18632/oncotarget.14174] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
74 Hansel C, Erschfeld S, Baues M, Lammers T, Weiskirchen R, Trautwein C, Kroy DC, Drescher HK. The Inhibitory T Cell Receptors PD1 and 2B4 Are Differentially Regulated on CD4 and CD8 T Cells in a Mouse Model of Non-alcoholic Steatohepatitis. Front Pharmacol 2019;10:244. [PMID: 30949049 DOI: 10.3389/fphar.2019.00244] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
75 Peng QH, Wang CH, Chen HM, Zhang RX, Pan ZZ, Lu ZH, Wang GY, Yue X, Huang W, Liu RY. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer. J Immunother Cancer 2021;9:e001638. [PMID: 33579737 DOI: 10.1136/jitc-2020-001638] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
76 Azcue P, Encío I, Guerrero Setas D, Suarez Alecha J, Galbete A, Mercado M, Vera R, Gomez-Dorronsoro ML. PD-L1 as a Prognostic Factor in Early-Stage Colon Carcinoma within the Immunohistochemical Molecular Subtype Classification. Cancers (Basel) 2021;13:1943. [PMID: 33920689 DOI: 10.3390/cancers13081943] [Reference Citation Analysis]
77 Bae SU, Jeong WK, Baek SK, Kim NK, Hwang I. Prognostic impact of programmed cell death ligand 1 expression on long-term oncologic outcomes in colorectal cancer. Oncol Lett 2018;16:5214-22. [PMID: 30250590 DOI: 10.3892/ol.2018.9264] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
78 Kim HR, Ha SJ, Hong MH, Heo SJ, Koh YW, Choi EC, Kim EK, Pyo KH, Jung I, Seo D, Choi J, Cho BC, Yoon SO. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Sci Rep 2016;6:36956. [PMID: 27841362 DOI: 10.1038/srep36956] [Cited by in Crossref: 134] [Cited by in F6Publishing: 136] [Article Influence: 22.3] [Reference Citation Analysis]
79 Le Flahec G, Badic B, Guibourg B, Doucet L, Bail J, Marcorelles P, Schick U, Uguen A. Mismatch repair–deficient colorectal cancer: a model of immunogenic and immune cell–rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells. Human Pathology 2018;72:135-43. [DOI: 10.1016/j.humpath.2017.09.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
80 Hou Y, Nitta H, Parwani AV, Li Z. PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers. Hum Pathol 2019;86:108-14. [PMID: 30633926 DOI: 10.1016/j.humpath.2018.12.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
81 Nebot-Bral L, Brandao D, Verlingue L, Rouleau E, Caron O, Despras E, El-Dakdouki Y, Champiat S, Aoufouchi S, Leary A, Marabelle A, Malka D, Chaput N, Kannouche PL. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine. Eur J Cancer 2017;84:290-303. [PMID: 28846956 DOI: 10.1016/j.ejca.2017.07.026] [Cited by in Crossref: 79] [Cited by in F6Publishing: 75] [Article Influence: 15.8] [Reference Citation Analysis]
82 Chen K, Cheng G, Zhang F, Zhang N, Li D, Jin J, Wu J, Ying L, Mao W, Su D. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Oncotarget 2016;7:30772-80. [PMID: 27120796 DOI: 10.18632/oncotarget.8956] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 12.6] [Reference Citation Analysis]
83 Billon E, Finetti P, Bertucci A, Niccoli P, Birnbaum D, Mamessier E, Bertucci F. PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma. Oncoimmunology 2019;8:e1655362. [PMID: 31646101 DOI: 10.1080/2162402X.2019.1655362] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
84 Taïeb J, André T, El Hajbi F, Barbier E, Toullec C, Kim S, Bouche O, Di Fiore F, Chauvenet M, Perrier H, Evesque L, Laurent-Puig P, Emile JF, Bez J, Lepage C, Tougeron D. Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. Dig Liver Dis 2021;53:318-23. [PMID: 33359404 DOI: 10.1016/j.dld.2020.11.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
85 Baby NT, Abdullah A, Kannan S. The scope of liquid biopsy in the clinical management of oral cancer. Int J Oral Maxillofac Surg 2021:S0901-5027(21)00292-7. [PMID: 34462176 DOI: 10.1016/j.ijom.2021.08.017] [Reference Citation Analysis]
86 Zhu J, Wen H, Bi R, Wu Y, Wu X. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma. J Gynecol Oncol 2017;28:e77. [PMID: 29027395 DOI: 10.3802/jgo.2017.28.e77] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
87 Hirt C, Papadimitropoulos A, Muraro MG, Mele V, Panopoulos E, Cremonesi E, Ivanek R, Schultz-Thater E, Droeser RA, Mengus C, Heberer M, Oertli D, Iezzi G, Zajac P, Eppenberger-Castori S, Tornillo L, Terracciano L, Martin I, Spagnoli GC. Bioreactor-engineered cancer tissue-like structures mimic phenotypes, gene expression profiles and drug resistance patterns observed "in vivo". Biomaterials 2015;62:138-46. [PMID: 26051518 DOI: 10.1016/j.biomaterials.2015.05.037] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
88 Kudo M. Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies. Liver Cancer 2019;8:413-26. [PMID: 32479569 DOI: 10.1159/000503254] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
89 Li W, Qie J, Zhang Y, Chang J. Spatiotemporal Changes in Checkpoint Molecule Expression. Adv Exp Med Biol 2020;1248:167-200. [PMID: 32185711 DOI: 10.1007/978-981-15-3266-5_8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
90 Abdul-Latif M, Townsend K, Dearman C, Shiu KK, Khan K. Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives. Cancer Treat Rev 2020;88:102030. [PMID: 32505807 DOI: 10.1016/j.ctrv.2020.102030] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
91 Soler A, Cayrefourcq L, Mazard T, Babayan A, Lamy PJ, Assou S, Assenat E, Pantel K, Alix-Panabières C. Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes. Sci Rep 2018;8:15931. [PMID: 30374140 DOI: 10.1038/s41598-018-34365-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
92 Ishiba T, Hoffmann AC, Usher J, Elshimali Y, Sturdevant T, Dang M, Jaimes Y, Tyagi R, Gonzales R, Grino M, Pinski JK, Barzi A, Raez LE, Eberhardt WE, Theegarten D, Lenz HJ, Uetake H, Danenberg PV, Danenberg K. Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. Biochem Biophys Res Commun. 2018;500:621-625. [PMID: 29679564 DOI: 10.1016/j.bbrc.2018.04.120] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
93 Onwe EE, Ghani FA, Abdullah M, Osman M, Zin RRM, Vivian AN, Mohtarrudin N. Predictive Potential of PD-L1, TYMS, and DCC Expressions in Treatment Outcome of Colorectal Carcinoma. Adv Exp Med Biol 2020;1292:97-112. [PMID: 32542457 DOI: 10.1007/5584_2020_521] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Koulis C, Yap R, Engel R, Jardé T, Wilkins S, Solon G, Shapiro JD, Abud H, McMurrick P. Personalized Medicine-Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer. Cancers (Basel) 2020;12:E812. [PMID: 32231042 DOI: 10.3390/cancers12040812] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
95 Chen G, Yang Z, Eshleman JR, Netto GJ, Lin MT. Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. Biomed Res Int 2016;2016:9850690. [PMID: 27699178 DOI: 10.1155/2016/9850690] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
96 Choi SH, Chang JS, Koo JS, Park JW, Sohn JH, Keum KC, Suh C, Kim YB. Differential Prognostic Impact of Strong PD-L1 Expression and 18F-FDG Uptake in Triple-negative Breast Cancer. American Journal of Clinical Oncology 2018;41:1049-57. [DOI: 10.1097/coc.0000000000000426] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
97 Gangadhar TC, Salama AK. Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. Onco Targets Ther 2015;8:929-37. [PMID: 25960664 DOI: 10.2147/OTT.S53164] [Cited by in Crossref: 7] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
98 Faluyi OO, Fitch P, Howie SEM. An increased CD25-positive intestinal regulatory T lymphocyte population is dependent upon Cox-2 activity in the Apcmin/+ model. Clin Exp Immunol 2018;191:32-41. [PMID: 28940183 DOI: 10.1111/cei.13055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
99 Bianconi M, Faloppi L, Lopez-beltran A, Cheng L, Cimadamore A, Gasparrini S, Massari F, Scarpelli M, Montironi R. Immunotherapy in genitourinary cancers: where are we going? Expert Review of Precision Medicine and Drug Development 2017;2:73-8. [DOI: 10.1080/23808993.2017.1321466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
100 Chiang S, Huang C, Ke T, Chen T, Lan Y, You Y, Chen WT, Chao KSC. Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers. Cancer Immunol Immunother 2019;68:283-96. [DOI: 10.1007/s00262-018-2275-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
101 Yamada R, Yamaguchi T, Iijima T, Wakaume R, Takao M, Koizumi K, Hishima T, Horiguchi SI. Differences in histological features and PD-L1 expression between sporadic microsatellite instability and Lynch-syndrome-associated disease in Japanese patients with colorectal cancer. Int J Clin Oncol 2018;23:504-13. [PMID: 29327160 DOI: 10.1007/s10147-018-1238-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
102 Ishii H, Azuma K, Kawahara A, Matsuo N, Tokito T, Kinoshita T, Yamada K, Sasada T, Akiba J, Hoshino T. Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy. Oncotarget 2017;8:61618-25. [PMID: 28977890 DOI: 10.18632/oncotarget.18651] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
103 Ma K, Qiao Y, Wang H, Wang S. Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma. Ann Transl Med 2020;8:1478. [PMID: 33313223 DOI: 10.21037/atm-20-6486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
104 Shiraliyeva N, Friedrichs J, Buettner R, Friedrichs N. PD-L1 expression in HNPCC-associated colorectal cancer. Pathol Res Pract 2017;213:1552-5. [PMID: 29033182 DOI: 10.1016/j.prp.2017.09.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
105 Beckers RK, Selinger CI, Vilain R, Madore J, Wilmott JS, Harvey K, Holliday A, Cooper CL, Robbins E, Gillett D, Kennedy CW, Gluch L, Carmalt H, Mak C, Warrier S, Gee HE, Chan C, McLean A, Walker E, McNeil CM, Beith JM, Swarbrick A, Scolyer RA, O'Toole SA. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology 2016;69:25-34. [PMID: 26588661 DOI: 10.1111/his.12904] [Cited by in Crossref: 108] [Cited by in F6Publishing: 122] [Article Influence: 18.0] [Reference Citation Analysis]
106 Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther 2020;5:22. [PMID: 32296018 DOI: 10.1038/s41392-020-0116-z] [Cited by in Crossref: 130] [Cited by in F6Publishing: 140] [Article Influence: 65.0] [Reference Citation Analysis]
107 Wen Q, Yang Z, Zhu J, Qiu Q, Dai H, Feng A, Xing L. Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC. Onco Targets Ther. 2020;13:12003-12013. [PMID: 33244242 DOI: 10.2147/ott.s261068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
108 Liao P, Wang H, Tang YL, Tang YJ, Liang XH. The Common Costimulatory and Coinhibitory Signaling Molecules in Head and Neck Squamous Cell Carcinoma. Front Immunol 2019;10:2457. [PMID: 31708918 DOI: 10.3389/fimmu.2019.02457] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
109 Lim YJ, Koh J, Kim K, Chie EK, Kim B, Lee KB, Jang JY, Kim SW, Oh DY, Bang YJ, Ha SW. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy. Radiother Oncol 2015;117:165-70. [PMID: 26235847 DOI: 10.1016/j.radonc.2015.07.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
110 Xu D, Dong P, Xiong Y, Chen R, Konno Y, Ihira K, Yue J, Watari H. PD-L1 Is a Tumor Suppressor in Aggressive Endometrial Cancer Cells and Its Expression Is Regulated by miR-216a and lncRNA MEG3. Front Cell Dev Biol 2020;8:598205. [PMID: 33363153 DOI: 10.3389/fcell.2020.598205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
111 Guillebon E, Roussille P, Frouin E, Tougeron D. Anti program death-1/anti program death-ligand 1 in digestive cancers. World J Gastrointest Oncol 2015; 7(8): 95-101 [PMID: 26306141 DOI: 10.4251/wjgo.v7.i8.95] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
112 Fang W, Zhang J, Hong S, Zhan J, Chen N, Qin T, Tang Y, Zhang Y, Kang S, Zhou T, Wu X, Liang W, Hu Z, Ma Y, Zhao Y, Tian Y, Yang Y, Xue C, Yan Y, Hou X, Huang P, Huang Y, Zhao H, Zhang L. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget 2014;5:12189-202. [PMID: 25361008 DOI: 10.18632/oncotarget.2608] [Cited by in Crossref: 196] [Cited by in F6Publishing: 201] [Article Influence: 28.0] [Reference Citation Analysis]
113 Roper E, Lum T, Palme CE, Ashford B, Ch'ng S, Ranson M, Boyer M, Clark J, Gupta R. PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma. Pathology 2017;49:499-505. [DOI: 10.1016/j.pathol.2017.04.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
114 Paul B, O'Neil BH, McRee AJ. Checkpoint inhibition for colorectal cancer: progress and possibilities. Immunotherapy 2016;8:693-704. [PMID: 27197538 DOI: 10.2217/imt-2016-0013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
115 Millard T, Kunk PR, Ramsdale E, Rahma OE. Current debate in the oncologic management of rectal cancer. World J Gastrointest Oncol 2016; 8(10): 715-724 [PMID: 27795811 DOI: 10.4251/wjgo.v8.i10.715] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
116 Wu X, Zhang H, Xing Q, Cui J, Li J, Li Y, Tan Y, Wang S. PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. Br J Cancer. 2014;111:1391-1399. [PMID: 25093496 DOI: 10.1038/bjc.2014.416] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 7.9] [Reference Citation Analysis]
117 Ahn H, Lee HJ, Lee JH, Cho HD, Oh MH, Son JW, Jang SH. Clinicopathological correlation of PD-L1 and TET1 expression with tumor-infiltrating lymphocytes in non-small cell lung cancer. Pathol Res Pract 2020;216:153188. [PMID: 32919305 DOI: 10.1016/j.prp.2020.153188] [Reference Citation Analysis]
118 Wang Y, Zhu C, Song W, Li J, Zhao G, Cao H. PD-L1 Expression and CD8+ T Cell Infiltration Predict a Favorable Prognosis in Advanced Gastric Cancer. J Immunol Res. 2018;2018:4180517. [PMID: 30003113 DOI: 10.1155/2018/4180517] [Cited by in Crossref: 16] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
119 Lim YJ, Koh J, Kim S, Jeon SR, Chie EK, Kim K, Kang GH, Han SW, Kim TY, Jeong SY, Park KJ, Wu HG. Chemoradiation-Induced Alteration of Programmed Death-Ligand 1 and CD8+ Tumor-Infiltrating Lymphocytes Identified Patients With Poor Prognosis in Rectal Cancer: A Matched Comparison Analysis. Int J Radiat Oncol Biol Phys 2017;99:1216-24. [PMID: 29165286 DOI: 10.1016/j.ijrobp.2017.07.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
120 Zhao YJ, Sun WP, Peng JH, Deng YX, Fang YJ, Huang J, Zhang HZ, Wan DS, Lin JZ, Pan ZZ. Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients. Cancer Manag Res 2018;10:1-11. [PMID: 29296096 DOI: 10.2147/CMAR.S153965] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
121 Zheng F, Dang J, Zha H, Zhang B, Lin M, Cheng F. PD-L1 Promotes Self-Renewal and Tumorigenicity of Malignant Melanoma Initiating Cells. Biomed Res Int 2017;2017:1293201. [PMID: 29250533 DOI: 10.1155/2017/1293201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
122 Rosenbaum MW, Bledsoe JR, Morales-oyarvide V, Huynh TG, Mino-kenudson M. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol 2016;29:1104-12. [DOI: 10.1038/modpathol.2016.95] [Cited by in Crossref: 122] [Cited by in F6Publishing: 130] [Article Influence: 20.3] [Reference Citation Analysis]
123 Schulz GB, Todorova R, Braunschweig T, Rodler S, Volz Y, Eismann L, Pfitzinger P, Jokisch F, Buchner A, Stief C, Mayr D, Casuscelli J. PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue? Urol Oncol 2021:S1078-1439(21)00260-X. [PMID: 34261585 DOI: 10.1016/j.urolonc.2021.06.001] [Reference Citation Analysis]
124 Parra ER, Villalobos P, Mino B, Rodriguez-Canales J. Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. Appl Immunohistochem Mol Morphol 2018;26:83-93. [PMID: 28719380 DOI: 10.1097/PAI.0000000000000531] [Cited by in Crossref: 62] [Cited by in F6Publishing: 41] [Article Influence: 15.5] [Reference Citation Analysis]
125 Nearchou A, Pentheroudakis G. The significance of tumor-associated immune response in molecular taxonomy, prognosis and therapy of colorectal cancer patients. Ann Transl Med 2016;4:271. [PMID: 27563658 DOI: 10.21037/atm.2016.05.54] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
126 George TJ, Franke AJ, Chakravarthy AB, Das P, Dasari A, El-Rayes BF, Hong TS, Kinsella TJ, Landry JC, Lee JJ, Monjazeb AM, Jacobs SA, Raben D, Rahma OE, Williams TM, Wu C, Coleman CN, Vikram B, Ahmed MM. National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer. Cancer 2019;125:2732-46. [PMID: 31017664 DOI: 10.1002/cncr.32150] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
127 Li Y, Liang L, Dai W, Cai G, Xu Y, Li X, Li Q, Cai S. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol Cancer 2016;15:55. [PMID: 27552968 DOI: 10.1186/s12943-016-0539-x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 129] [Article Influence: 18.8] [Reference Citation Analysis]
128 Yoshida S, Nagatsuka H, Nakano K, Kogashiwa Y, Ebihara Y, Yano M, Yasuda M. Significance of PD-L1 Expression in Tongue Cancer Development. Int J Med Sci 2018;15:1723-30. [PMID: 30588196 DOI: 10.7150/ijms.27860] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
129 Ogino S, Nowak JA, Hamada T, Phipps AI, Peters U, Milner DA, Giovannucci EL, Nishihara R, Giannakis M, Garrett WS, Song M. Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. Gut. 2018;67:1168-1180. [PMID: 29437869 DOI: 10.1136/gutjnl-2017-315537] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 23.3] [Reference Citation Analysis]
130 Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014;94:107-16. [PMID: 24217091 DOI: 10.1038/labinvest.2013.130] [Cited by in Crossref: 489] [Cited by in F6Publishing: 524] [Article Influence: 54.3] [Reference Citation Analysis]
131 Birnbaum DJ, Finetti P, Lopresti A, Gilabert M, Poizat F, Turrini O, Raoul JL, Delpero JR, Moutardier V, Birnbaum D, Mamessier E, Bertucci F. Prognostic value of PDL1 expression in pancreatic cancer. Oncotarget 2016;7:71198-210. [PMID: 27589570 DOI: 10.18632/oncotarget.11685] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 11.5] [Reference Citation Analysis]
132 Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J, Nielsen GP, Chebib I, Ferrone S, Wang X, Wang Y, Mankin H, Hornicek FJ, Duan Z. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res 2014;2:690-8. [PMID: 24866169 DOI: 10.1158/2326-6066.CIR-13-0224] [Cited by in Crossref: 114] [Cited by in F6Publishing: 80] [Article Influence: 14.3] [Reference Citation Analysis]
133 Wang B, Li F, Guo L, Lu S, Ma J, Ma Y, Meng Y, Wang J, Zhou X, Fu W. Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell. World J Surg Oncol 2020;18:196. [PMID: 32767974 DOI: 10.1186/s12957-020-01970-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
134 Kim KH, Choi KU, Kim A, Lee SJ, Lee JH, Suh DS, Kwon BS, Hwang C. PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma. J Ovarian Res 2019;12:56. [PMID: 31208449 DOI: 10.1186/s13048-019-0526-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
135 Chen H, Molberg K, Strickland AL, Castrillon DH, Carrick K, Jiang Q, Niu S, Rivera-Colon G, Gwin K, Hinson S, Lea J, Miller DS, Zheng W, Lucas E. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma. Am J Surg Pathol 2020;44:1050-60. [PMID: 32384321 DOI: 10.1097/PAS.0000000000001503] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
136 Tai H, Yang Q, Wu Z, Sun S, Cao R, Xi Y, Zhao R, Zhang M, Zhang Z, Xu C. PD-L1 Expression Predicts a Distinct Prognosis in Krukenberg Tumor with Corresponding Origins. J Immunol Res 2018;2018:9485285. [PMID: 29854854 DOI: 10.1155/2018/9485285] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
137 Lee VH, Lo AW, Leung CY, Shek WH, Kwong DL, Lam KO, Tong CC, Sze CK, Leung TW. Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma. PLoS One 2016;11:e0157969. [PMID: 27341634 DOI: 10.1371/journal.pone.0157969] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 5.2] [Reference Citation Analysis]
138 Zou J, Wu D, Li T, Wang X, Liu Y, Tan S. Association of PD-L1 gene rs4143815 C>G polymorphism and human cancer susceptibility: A systematic review and meta-analysis. Pathol Res Pract. 2019;215:229-234. [PMID: 30552042 DOI: 10.1016/j.prp.2018.12.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
139 Wyss J, Dislich B, Koelzer VH, Galván JA, Dawson H, Hädrich M, Inderbitzin D, Lugli A, Zlobec I, Berger MD. Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients. Clin Colorectal Cancer 2019;18:e20-38. [PMID: 30389315 DOI: 10.1016/j.clcc.2018.09.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
140 Kim ST, Ha SY, Lee S, Ahn S, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim KM, Park YS. The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. J Cancer. 2016;7:484-489. [PMID: 26958083 DOI: 10.7150/jca.13711] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 10.8] [Reference Citation Analysis]
141 Polesel J, Menegaldo A, Tirelli G, Giacomarra V, Guerrieri R, Baboci L, Casarotto M, Lupato V, Fanetti G, Boscolo-Rizzo P, Fratta E. Prognostic Significance of PD-L1 Expression In Patients With Primary Oropharyngeal Squamous Cell Carcinoma: A Meta-Analysis. Front Oncol 2021;11:787864. [PMID: 34900743 DOI: 10.3389/fonc.2021.787864] [Reference Citation Analysis]
142 Du X, Wang L, Shen B, He H, Chang H, Wei B. CLINICAL SIGNIFICANCE OF PD-L1 EXPRESSION IN PARATHYROID CANCER. Acta Endocrinol (Buchar) 2016;12:383-6. [PMID: 31149119 DOI: 10.4183/aeb.2016.383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
143 Dai C, Wang M, Lu J, Dai Z, Lin S, Yang P, Tian T, Liu X, Min W, Dai Z. Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis. Onco Targets Ther 2017;10:3625-34. [PMID: 28769571 DOI: 10.2147/OTT.S138044] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
144 Hu XY, Zhang W, Hu Y, Zhang Y, Gong R, Liang JY, Liu L. A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer. J Huazhong Univ Sci Technolog Med Sci 2016;36:313-20. [PMID: 27376797 DOI: 10.1007/s11596-016-1585-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
145 Green DS, Nunes AT, Annunziata CM, Zoon KC. Monocyte and interferon based therapy for the treatment of ovarian cancer. Cytokine Growth Factor Rev 2016;29:109-15. [PMID: 27026228 DOI: 10.1016/j.cytogfr.2016.02.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
146 Pedrosa L, Esposito F, Thomson TM, Maurel J. The Tumor Microenvironment in Colorectal Cancer Therapy. Cancers (Basel) 2019;11:E1172. [PMID: 31416205 DOI: 10.3390/cancers11081172] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
147 Zhang Y, Luo Y, Qin SL, Mu YF, Qi Y, Yu MH, Zhong M. The clinical impact of ICOS signal in colorectal cancer patients. Oncoimmunology. 2016;5:e1141857. [PMID: 27467961 DOI: 10.1080/2162402x.2016.1141857] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
148 Duverger L, Osio A, Cribier B, Mortier L, De Masson A, Basset-seguin N, Lebbé C, Battistella M. Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas. Cancer Immunol Immunother 2019;68:951-60. [DOI: 10.1007/s00262-019-02334-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
149 Pang SW, Awi NJ, Armon S, Lim WW, Low JS, Peh KB, Peh SC, Teow SY. Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC). Diagnostics (Basel) 2019;10:E9. [PMID: 31877940 DOI: 10.3390/diagnostics10010009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
150 Zeng L, Huang W, Cao Z, Zheng B, Liu X, Guo L, Feng X. The correlation of clinicopathological features and prognosis in extranodal natural killer/T cell lymphoma: a report of 42 cases in the early stage. Ann Hematol 2019;98:1467-76. [PMID: 30895352 DOI: 10.1007/s00277-019-03643-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
151 Jesinghaus M, Steiger K, Slotta-Huspenina J, Drecoll E, Pfarr N, Meyer P, Konukiewitz B, Bettstetter M, Wieczorek K, Ott K, Feith M, Langer R, Weichert W, Specht K, Boxberg M. Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping. Oncotarget 2017;8:46756-68. [PMID: 28657901 DOI: 10.18632/oncotarget.18606] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
152 Guo W, Zhang F, Shao F, Wang P, Li Z, Yang X, He Z, Shi S, Gao Y, He J. PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma. Hum Pathol 2019;84:291-8. [PMID: 30296523 DOI: 10.1016/j.humpath.2018.09.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
153 Henick BS, Herbst RS, Goldberg SB. The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. Expert Opin Ther Targets 2014;18:1407-20. [PMID: 25331677 DOI: 10.1517/14728222.2014.955794] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
154 Shahnam A, Paver E, Nguyen B, Fadia M, Ali S. Prognostic Utility of CDX2 and PD-L1 in Rectal Cancer. Appl Immunohistochem Mol Morphol 2020;28:e53. [PMID: 31166198 DOI: 10.1097/PAI.0000000000000752] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali HR, Viens P, Caldas C, Birnbaum D, Bertucci F. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015;6:5449-5464. [PMID: 25669979 DOI: 10.18632/oncotarget.3216] [Cited by in Crossref: 261] [Cited by in F6Publishing: 261] [Article Influence: 43.5] [Reference Citation Analysis]
156 Kourea H, Kotoula V. Towards tumor immunodiagnostics. Ann Transl Med 2016;4:263. [PMID: 27563650 DOI: 10.21037/atm.2016.07.07] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
157 Ravelli A, Reuben JM, Lanza F, Anfossi S, Cappelletti MR, Zanotti L, Gobbi A, Milani M, Spada D, Pedrazzoli P, Martino M, Bottini A, Generali D; Solid Tumor Working Party of the European Blood and Marrow Transplantation Society (EBMT). Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity. Expert Rev Anticancer Ther 2015;15:689-702. [PMID: 25927868 DOI: 10.1586/14737140.2015.1042864] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
158 Zhao L, Yu H, Yi S, Peng X, Su P, Xiao Z, Liu R, Tang A, Li X, Liu F, Shen S. The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. Oncotarget. 2016;7:45370-45384. [PMID: 27248318 DOI: 10.18632/oncotarget.9659] [Cited by in Crossref: 107] [Cited by in F6Publishing: 118] [Article Influence: 26.8] [Reference Citation Analysis]
159 Banerji U, Workman P. Critical parameters in targeted drug development: the pharmacological audit trail. Seminars in Oncology 2016;43:436-45. [DOI: 10.1053/j.seminoncol.2016.06.001] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 7.7] [Reference Citation Analysis]
160 Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-corish M, Yip P, Yu B, O’toole SA, Mccaughan BC, Yearley JH, Horvath LG, Kao S, Boyer M, Scolyer RA. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer 2015;89:181-8. [DOI: 10.1016/j.lungcan.2015.05.007] [Cited by in Crossref: 164] [Cited by in F6Publishing: 182] [Article Influence: 23.4] [Reference Citation Analysis]
161 Emami F, Banstola A, Vatanara A, Lee S, Kim JO, Jeong JH, Yook S. Doxorubicin and Anti-PD-L1 Antibody Conjugated Gold Nanoparticles for Colorectal Cancer Photochemotherapy. Mol Pharm 2019;16:1184-99. [PMID: 30698975 DOI: 10.1021/acs.molpharmaceut.8b01157] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 18.3] [Reference Citation Analysis]
162 Wei XL, Wu QN, Chen DL, Zeng ZL, Lu JB, Liu ZX, Ju HQ, Ren C, Pan ZZ, Wang FH, Xu RH. The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer. J Cancer 2018;9:4325-33. [PMID: 30519336 DOI: 10.7150/jca.27735] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
163 Hecht M, Büttner-Herold M, Erlenbach-Wünsch K, Haderlein M, Croner R, Grützmann R, Hartmann A, Fietkau R, Distel LV. PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis. Eur J Cancer 2016;65:52-60. [PMID: 27468145 DOI: 10.1016/j.ejca.2016.06.015] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 11.5] [Reference Citation Analysis]
164 Randrian V, Desette A, Emambux S, Derangere V, Roussille P, Frouin E, Godet J, Karayan-Tapon L, Ghiringhelli F, Tougeron D. New Artificial Intelligence Score and Immune Infiltrates as Prognostic Factors in Colorectal Cancer With Brain Metastases. Front Immunol 2021;12:750407. [PMID: 34733283 DOI: 10.3389/fimmu.2021.750407] [Reference Citation Analysis]
165 Bae SB, Cho HD, Oh MH, Lee JH, Jang SH, Hong SA, Cho J, Kim SY, Han SW, Lee JE, Kim HJ, Lee HJ. Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer. J Breast Cancer 2016;19:242-51. [PMID: 27721873 DOI: 10.4048/jbc.2016.19.3.242] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 5.5] [Reference Citation Analysis]
166 Yang F, Zeng Z, Li J, Zheng Y, Wei F, Ren X. PD-1/PD-L1 Axis, Rather Than High-Mobility Group Alarmins or CD8+ Tumor-Infiltrating Lymphocytes, Is Associated With Survival in Head and Neck Squamous Cell Carcinoma Patients Who Received Surgical Resection. Front Oncol 2018;8:604. [PMID: 30619746 DOI: 10.3389/fonc.2018.00604] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
167 Kasahara N, Kaira K, Yamaguchi K, Masubuchi H, Tsurumaki H, Hara K, Koga Y, Sakurai R, Higuchi T, Handa T, Oyama T, Yokobori T, Shimizu K, Asao T, Hisada T. Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer. Lung Cancer 2019;134:180-6. [PMID: 31319979 DOI: 10.1016/j.lungcan.2019.06.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
168 Miao L, Lu Y, Xu Y, Zhang G, Huang Z, Gong L, Fan Y. PD-L1 and c-MET expression and survival in patients with small cell lung cancer. Oncotarget 2017;8:53978-88. [PMID: 28903317 DOI: 10.18632/oncotarget.9765] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
169 Klose J, Lasitschka F, Horsch C, Strowitzki MJ, Bruckner T, Volz C, Schmidt T, Schneider M. Prognostic relevance of programmed death-ligand 1 expression and microsatellite status in small bowel adenocarcinoma. Scand J Gastroenterol 2020;55:321-9. [PMID: 32191146 DOI: 10.1080/00365521.2020.1734073] [Reference Citation Analysis]
170 Kong P, Wang J, Song Z, Liu S, He W, Jiang C, Xie Q, Yang L, Xia X, Xia L. Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status. J Cancer 2019;10:1745-54. [PMID: 31205530 DOI: 10.7150/jca.25187] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
171 Lee KS, Kwak Y, Ahn S, Shin E, Oh H, Kim D, Kang S, Choe G, Kim WH, Lee HS. Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer. Cancer Immunol Immunother 2017;66:927-39. [DOI: 10.1007/s00262-017-1999-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 9.6] [Reference Citation Analysis]
172 Yang L, Xue R, Pan C. Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis. Onco Targets Ther 2019;12:3671-82. [PMID: 31190869 DOI: 10.2147/OTT.S190168] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
173 Choi YY, Kim H, Shin S, Kim HY, Lee J, Yang H, Kim WH, Kim Y, Kook M, Park YK, Kim H, Lee HS, Lee KH, Gu MJ, Choi SH, Hong S, Kim JW, Hyung WJ, Noh SH, Cheong J. Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study. Annals of Surgery 2019;270:309-16. [DOI: 10.1097/sla.0000000000002803] [Cited by in Crossref: 72] [Cited by in F6Publishing: 54] [Article Influence: 24.0] [Reference Citation Analysis]
174 Schalper KA. PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer. Oncoimmunology. 2014;3:e29288. [PMID: 25083339 DOI: 10.4161/onci.29288] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 5.8] [Reference Citation Analysis]
175 Vanderstraeten A, Luyten C, Verbist G, Tuyaerts S, Amant F. Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunol Immunother 2014;63:545-57. [PMID: 24658839 DOI: 10.1007/s00262-014-1537-8] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 9.1] [Reference Citation Analysis]
176 Combaz-Lair C, Galateau-Sallé F, McLeer-Florin A, Le Stang N, David-Boudet L, Duruisseaux M, Ferretti GR, Brambilla E, Lebecque S, Lantuejoul S. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. Hum Pathol 2016;52:9-18. [PMID: 26980049 DOI: 10.1016/j.humpath.2016.01.010] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 9.3] [Reference Citation Analysis]
177 Yaghoubi N, Soltani A, Ghazvini K, Hassanian SM, Hashemy SI. PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer. Biomedicine & Pharmacotherapy 2019;110:312-8. [DOI: 10.1016/j.biopha.2018.11.105] [Cited by in Crossref: 95] [Cited by in F6Publishing: 94] [Article Influence: 31.7] [Reference Citation Analysis]
178 Inaguma S, Lasota J, Wang Z, Felisiak-Golabek A, Ikeda H, Miettinen M. Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. Mod Pathol 2017;30:278-85. [PMID: 27813511 DOI: 10.1038/modpathol.2016.185] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 8.2] [Reference Citation Analysis]
179 Zeng J, Zhang XK, Chen HD, Zhong ZH, Wu QL, Lin SX. Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. Oncotarget 2016;7:8944-55. [PMID: 26771840 DOI: 10.18632/oncotarget.6884] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
180 Sideras K, Biermann K, Verheij J, Takkenberg BR, Mancham S, Hansen BE, Schutz HM, de Man RA, Sprengers D, Buschow SI, Verseput MC, Boor PP, Pan Q, van Gulik TM, Terkivatan T, Ijzermans JN, Beuers UH, Sleijfer S, Bruno MJ, Kwekkeboom J. PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma. Oncoimmunology. 2017;6:e1273309. [PMID: 28344887 DOI: 10.1080/2162402x.2016.1273309] [Cited by in Crossref: 74] [Cited by in F6Publishing: 47] [Article Influence: 14.8] [Reference Citation Analysis]
181 Parra ER, Behrens C, Rodriguez-Canales J, Lin H, Mino B, Blando J, Zhang J, Gibbons DL, Heymach JV, Sepesi B, Swisher SG, Weissferdt A, Kalhor N, Izzo J, Kadara H, Moran C, Lee JJ, Wistuba II. Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients. Clin Cancer Res 2016;22:6278-89. [PMID: 27252415 DOI: 10.1158/1078-0432.CCR-15-2443] [Cited by in Crossref: 90] [Cited by in F6Publishing: 54] [Article Influence: 15.0] [Reference Citation Analysis]
182 Thierauf J, Veit JA, Affolter A, Bergmann C, Grünow J, Laban S, Lennerz JK, Grünmüller L, Mauch C, Plinkert PK, Hess J, Hoffmann TK. Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck. Melanoma Research 2015;25:503-9. [DOI: 10.1097/cmr.0000000000000197] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 5.9] [Reference Citation Analysis]
183 Herrera-Martínez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Gálvez Moreno MA, Luque RM, Castaño JP, de Herder WW, Feelders RA. Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs 2019;79:21-42. [PMID: 30560479 DOI: 10.1007/s40265-018-1033-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
184 Teng F, Meng X, Kong L, Mu D, Zhu H, Liu S, Zhang J, Yu J. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer. Transl Res 2015;166:721-732.e1. [PMID: 26209749 DOI: 10.1016/j.trsl.2015.06.019] [Cited by in Crossref: 57] [Cited by in F6Publishing: 61] [Article Influence: 8.1] [Reference Citation Analysis]
185 Tsuruoka K, Horinouchi H, Goto Y, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Asakura K, Nakagawa K, Sakurai H, Watanabe SI, Tsuta K, Ohe Y. PD-L1 expression in neuroendocrine tumors of the lung. Lung Cancer 2017;108:115-20. [PMID: 28625622 DOI: 10.1016/j.lungcan.2017.03.006] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 11.4] [Reference Citation Analysis]
186 Bertucci F, Finetti P, Mamessier E, Pantaleo MA, Astolfi A, Ostrowski J, Birnbaum D. PDL1 expression is an independent prognostic factor in localized GIST. Oncoimmunology 2015;4:e1002729. [PMID: 26155391 DOI: 10.1080/2162402X.2014.1002729] [Cited by in Crossref: 46] [Cited by in F6Publishing: 26] [Article Influence: 6.6] [Reference Citation Analysis]
187 Li YM, Yu JM, Liu ZY, Yang HJ, Tang J, Chen ZN. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8+ T Cells in Non-Small Cell Lung Cancer. Int J Mol Sci 2019;20:E5138. [PMID: 31627272 DOI: 10.3390/ijms20205138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
188 Berardi R, Goteri G, Brunelli A, Pagliaretta S, Paolucci V, Caramanti M, Rinaldi S, Refai M, Pompili C, Morgese F, Torniai M, Marcantognini G, Ricci G, Mazzanti P, Onofri A, Bianchi F, Sabbatini A, Cascinu S. Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach. Expert Opin Ther Targets 2020;24:937-43. [PMID: 32662701 DOI: 10.1080/14728222.2020.1790529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
189 Elfishawy M, Abd-ELaziz SA, Hegazy A, El-Yasergy DF. Immunohistochemical Expression of Programmed Death Ligand-1 (PDL-1) in Colorectal carcinoma and Its Correlation with Stromal Tumor Infiltrating Lymphocytes. Asian Pac J Cancer Prev 2020;21:225-32. [PMID: 31983188 DOI: 10.31557/APJCP.2020.21.1.225] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
190 Jiang W, Li T, Wang J, Jiao R, Shi X, Huang X, Ji G. miR-140-3p Suppresses Cell Growth And Induces Apoptosis In Colorectal Cancer By Targeting PD-L1. Onco Targets Ther 2019;12:10275-85. [PMID: 31819512 DOI: 10.2147/OTT.S226465] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
191 Zhang Y, Kang S, Shen J, He J, Jiang L, Wang W, Guo Z, Peng G, Chen G, He J, Liang W. Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis. Medicine (Baltimore) 2015;94:e515. [PMID: 25674748 DOI: 10.1097/MD.0000000000000515] [Cited by in Crossref: 64] [Cited by in F6Publishing: 47] [Article Influence: 9.1] [Reference Citation Analysis]
192 Baptista MZ, Sarian LO, Derchain SF, Pinto GA, Vassallo J. Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum Pathol. 2016;47:78-84. [PMID: 26541326 DOI: 10.1016/j.humpath.2015.09.006] [Cited by in Crossref: 117] [Cited by in F6Publishing: 128] [Article Influence: 16.7] [Reference Citation Analysis]
193 Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S, Zhang Y, He X, Zhou T, Qin T. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation. J Thorac Oncol. 2015;10:910-923. [PMID: 25658629 DOI: 10.1097/jto.0000000000000500] [Cited by in Crossref: 293] [Cited by in F6Publishing: 238] [Article Influence: 48.8] [Reference Citation Analysis]
194 Kawamoto K, Miyoshi H, Suzuki T, Kiyasu J, Yokoyama S, Sasaki Y, Sone H, Seto M, Takizawa J, Ohshima K. Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients. Hematol Oncol 2018;36:591-9. [PMID: 29602174 DOI: 10.1002/hon.2506] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
195 Koh YW, Han JH, Yoon DH, Suh C, Huh J. PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma. Ann Hematol 2017;96:1883-90. [PMID: 28842748 DOI: 10.1007/s00277-017-3115-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
196 Zhao Y, Wang Y, Wang Q. HNRNPL affects the proliferation and apoptosis of colorectal cancer cells by regulating PD-L1. Pathol Res Pract 2021;218:153320. [PMID: 33418347 DOI: 10.1016/j.prp.2020.153320] [Reference Citation Analysis]
197 Que Y, Xiao W, Guan YX, Liang Y, Yan SM, Chen HY, Li QQ, Xu BS, Zhou ZW, Zhang X. PD-L1 Expression Is Associated with FOXP3+ Regulatory T-Cell Infiltration of Soft Tissue Sarcoma and Poor Patient Prognosis. J Cancer. 2017;8:2018-2025. [PMID: 28819402 DOI: 10.7150/jca.18683] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 9.4] [Reference Citation Analysis]
198 Dunne MR, Ryan C, Nolan B, Tosetto M, Geraghty R, Winter DC, O'Connell PR, Hyland JM, Doherty GA, Sheahan K, Ryan EJ, Fletcher JM. Enrichment of Inflammatory IL-17 and TNF-α Secreting CD4(+) T Cells within Colorectal Tumors despite the Presence of Elevated CD39(+) T Regulatory Cells and Increased Expression of the Immune Checkpoint Molecule, PD-1. Front Oncol 2016;6:50. [PMID: 27014625 DOI: 10.3389/fonc.2016.00050] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
199 Koh YW, Jeon YK, Yoon DH, Suh C, Huh J. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma. Tumour Biol 2016;37:7507-14. [PMID: 26678894 DOI: 10.1007/s13277-015-4622-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
200 Digiacomo N, Bolzacchini E, Veronesi G, Cerutti R, Sahnane N, Pinotti G, Bregni M, Artale S, Verusio C, Crivelli F, Capella C, Sessa F, Furlan D. Neuroendocrine Differentiation, Microsatellite Instability, and Tumor-infiltrating Lymphocytes in Advanced Colorectal Cancer With BRAF Mutation. Clin Colorectal Cancer 2019;18:e251-60. [PMID: 30638691 DOI: 10.1016/j.clcc.2018.12.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
201 Schmidt LH, Kümmel A, Görlich D, Mohr M, Bröckling S, Mikesch JH, Grünewald I, Marra A, Schultheis AM, Wardelmann E, Müller-Tidow C, Spieker T, Schliemann C, Berdel WE, Wiewrodt R, Hartmann W. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. PLoS One 2015;10:e0136023. [PMID: 26313362 DOI: 10.1371/journal.pone.0136023] [Cited by in Crossref: 137] [Cited by in F6Publishing: 147] [Article Influence: 19.6] [Reference Citation Analysis]
202 Wu Z, Yang L, Shi L, Song H, Shi P, Yang T, Fan R, Jiang T, Song J. Prognostic Impact of Adenosine Receptor 2 (A2aR) and Programmed Cell Death Ligand 1 (PD-L1) Expression in Colorectal Cancer. Biomed Res Int 2019;2019:8014627. [PMID: 31275983 DOI: 10.1155/2019/8014627] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
203 Nalli M, Puxeddu M, La Regina G, Gianni S, Silvestri R. Emerging Therapeutic Agents for Colorectal Cancer. Molecules 2021;26:7463. [DOI: 10.3390/molecules26247463] [Reference Citation Analysis]
204 Dai C, Geng R, Wang C, Wong A, Qing M, Hu J, Sun Y, Lo AW, Li J. Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer. Mol Oncol. 2016;10:1551-1558. [PMID: 27720576 DOI: 10.1016/j.molonc.2016.09.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
205 Monette A, Bergeron D, Ben Amor A, Meunier L, Caron C, Mes-Masson AM, Kchir N, Hamzaoui K, Jurisica I, Lapointe R. Immune-enrichment of non-small cell lung cancer baseline biopsies for multiplex profiling define prognostic immune checkpoint combinations for patient stratification. J Immunother Cancer 2019;7:86. [PMID: 30922393 DOI: 10.1186/s40425-019-0544-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
206 Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20:5064-5074. [PMID: 24714771 DOI: 10.1158/1078-0432.ccr-13-3271] [Cited by in Crossref: 1424] [Cited by in F6Publishing: 921] [Article Influence: 178.0] [Reference Citation Analysis]
207 Valentini AM, Di Pinto F, Cariola F, Guerra V, Giannelli G, Caruso ML, Pirrelli M. PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments. Oncotarget 2018;9:8584-96. [PMID: 29492219 DOI: 10.18632/oncotarget.24196] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
208 Calik I, Calik M, Turken G, Ozercan IH, Dagli AF, Artas G, Sarikaya B. Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer. Medicina (Kaunas) 2019;55:E723. [PMID: 31683723 DOI: 10.3390/medicina55110723] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
209 Görgün G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, White RE, Singh A, Ohguchi H, Suzuki R, Kikuchi S, Harada T, Hideshima T, Tai YT, Laubach JP, Raje N, Magrangeas F, Minvielle S, Avet-Loiseau H, Munshi NC, Dorfman DM, Richardson PG, Anderson KC. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res 2015;21:4607-18. [PMID: 25979485 DOI: 10.1158/1078-0432.CCR-15-0200] [Cited by in Crossref: 179] [Cited by in F6Publishing: 120] [Article Influence: 25.6] [Reference Citation Analysis]
210 Huemer F, Klieser E, Neureiter D, Schlintl V, Rinnerthaler G, Pagès F, Kirilovsky A, El Sissy C, Iglseder W, Singhartinger F, Jäger T, Dinnewitzer A, Zaborsky N, Steiner M, Greil R, Weiss L. Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy. J Clin Med 2020;9:E2775. [PMID: 32867256 DOI: 10.3390/jcm9092775] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
211 Berntsson J, Eberhard J, Nodin B, Leandersson K, Larsson AH, Jirström K. Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis. Oncoimmunology 2018;7:e1465165. [PMID: 30221062 DOI: 10.1080/2162402X.2018.1465165] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
212 Kollmann D, Ignatova D, Jedamzik J, Chang YT, Jomrich G, Baierl A, Kazakov D, Michal M, French LE, Hoetzenecker W, Schatton T, Asari R, Preusser M, Gnant M, Guenova E, Schoppmann SF. PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma. Oncoimmunology 2018;7:e1435226. [PMID: 29872575 DOI: 10.1080/2162402X.2018.1435226] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
213 Koh YW, Han JH, Park SY, Yoon DH, Suh C, Huh J. GLUT1 as a Prognostic Factor for Classical Hodgkin's Lymphoma: Correlation with PD-L1 and PD-L2 Expression. J Pathol Transl Med 2017;51:152-8. [PMID: 28219001 DOI: 10.4132/jptm.2016.11.03] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
214 Jiang L, Wang L, Li PF, Zhang XK, Chen JW, Qiu HJ, Wu XD, Zhang B. Positive Expression of Programmed Death ligand-1 Correlates With Superior Outcomes and Might Be a Therapeutic Target in Primary Pulmonary Lymphoepithelioma-Like Carcinoma. Onco Targets Ther. 2015;8:1451-1457. [PMID: 26109869 DOI: 10.2147/ott.s84234] [Cited by in Crossref: 8] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
215 Salmaninejad A, Khoramshahi V, Azani A, Soltaninejad E, Aslani S, Zamani MR, Zal M, Nesaei A, Hosseini SM. PD-1 and cancer: molecular mechanisms and polymorphisms. Immunogenetics. 2018;70:73-86. [PMID: 28642997 DOI: 10.1007/s00251-017-1015-5] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
216 Ge J, Zhu L, Zhou J, Li G, Li Y, Li S, Wu Z, Rong J, Yuan H, Liu Y, Chi Q, Piao D, Zhao Y, Cui B. Association between co-inhibitory molecule gene tagging single nucleotide polymorphisms and the risk of colorectal cancer in Chinese. J Cancer Res Clin Oncol 2015;141:1533-44. [PMID: 25604582 DOI: 10.1007/s00432-015-1915-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
217 Mansour MSI, Seidal T, Mager U, Baigi A, Dobra K, Dejmek A. Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining. Cancer Cytopathol 2017;125:908-17. [PMID: 28922567 DOI: 10.1002/cncy.21917] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
218 Xing X, Guo J, Ding G, Li B, Dong B, Feng Q, Li S, Zhang J, Ying X, Cheng X, Guo T, Du H, Hu Y, Zhou T, Wang X, Li L, Li Q, Xie M, Li L, Gao X, Shan F, Li Z, Jia S, Wen X, Wang J, Ji J. Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. Oncoimmunology 2018;7:e1356144. [PMID: 29399387 DOI: 10.1080/2162402X.2017.1356144] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 12.6] [Reference Citation Analysis]
219 Cao H, Wang Q, Gao Z, Yu Z, Wu Y, Lu Q. Programmed death-ligand 1 and survival in colorectal cancers: A meta-analysis. Int J Biol Markers 2019;34:356-63. [PMID: 31564188 DOI: 10.1177/1724600819876952] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
220 Zaravinos A, Roufas C, Nagara M, de Lucas Moreno B, Oblovatskaya M, Efstathiades C, Dimopoulos C, Ayiomamitis GD. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer. J Exp Clin Cancer Res 2019;38:364. [PMID: 31429779 DOI: 10.1186/s13046-019-1372-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
221 Corrò C, Dutoit V, Koessler T. Emerging Trends for Radio-Immunotherapy in Rectal Cancer. Cancers (Basel) 2021;13:1374. [PMID: 33803620 DOI: 10.3390/cancers13061374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
222 Bertucci F, Finetti P, Perrot D, Leroux A, Collin F, Le Cesne A, Coindre JM, Blay JY, Birnbaum D, Mamessier E. PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. Oncoimmunology 2017;6:e1278100. [PMID: 28405501 DOI: 10.1080/2162402X.2016.1278100] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 8.6] [Reference Citation Analysis]
223 Miller T, Mccoy M, Hemmings C, Bulsara M, Iacopetta B, Platell C. The prognostic value of cancer stem-like cell markers SOX2 and CD133 in stage III colon cancer is modified by expression of the immune-related markers FoxP3, PD-L1 and CD3. Pathology 2017;49:721-30. [DOI: 10.1016/j.pathol.2017.08.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
224 Ren G, Hao X, Yang S, Chen J, Qiu G, Ang KP, Mohd Tamrin MI. 10H-3,6-Diazaphenothiazines triggered the mitochondrial-dependent and cell death receptor-dependent apoptosis pathways and further increased the chemosensitivity of MCF-7 breast cancer cells via inhibition of AKT1 pathways. J Biochem Mol Toxicol 2020;:e22544. [PMID: 32619082 DOI: 10.1002/jbt.22544] [Reference Citation Analysis]
225 Lee KS, Kim BH, Oh HK, Kim DW, Kang SB, Kim H, Shin E. Programmed cell death ligand-1 protein expression and CD274/PD-L1 gene amplification in colorectal cancer: Implications for prognosis. Cancer Sci 2018;109:2957-69. [PMID: 29949671 DOI: 10.1111/cas.13716] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
226 Burmeister K, Quagliata L, Andreozzi M, Eppenberger-Castori S, Matter MS, Perrina V, Grobholz R, Jochum W, Horber D, Moosmann P, Lehmann F, Köberle D, Ng CK, Piscuoglio S, Tornillo L, Terracciano LM. Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes. PLoS One 2017;12:e0175563. [PMID: 28403223 DOI: 10.1371/journal.pone.0175563] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
227 Weissferdt A, Fujimoto J, Kalhor N, Rodriguez J, Bassett R, Wistuba II, Moran CA. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. Mod Pathol 2017;30:826-33. [DOI: 10.1038/modpathol.2017.6] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 9.4] [Reference Citation Analysis]
228 Passardi A, Canale M, Valgiusti M, Ulivi P. Immune Checkpoints as a Target for Colorectal Cancer Treatment. Int J Mol Sci. 2017;18:1324. [PMID: 28635639 DOI: 10.3390/ijms18061324] [Cited by in Crossref: 62] [Cited by in F6Publishing: 63] [Article Influence: 12.4] [Reference Citation Analysis]
229 Gentzler R, Hall R, Kunk PR, Gaughan E, Dillon P, Slingluff CL Jr, Rahma OE. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. Immunotherapy 2016;8:583-600. [PMID: 27140411 DOI: 10.2217/imt-2015-0029] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 9.2] [Reference Citation Analysis]
230 Huang B, Chen L, Bao C, Sun C, Li J, Wang L, Zhang X. The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysis. Onco Targets Ther. 2015;8:2617-2625. [PMID: 26451118 DOI: 10.2147/ott.s91025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
231 Miyamoto E, Chen-yoshikawa TF, Ueshima C, Yoshizawa A, Hamaji M, Yamamoto T, Kawada K, Haga H, Sakai Y, Date H. Transition of the programmed death 1 pathway from the primary colorectal cancer to its corresponding pulmonary metastasis. J Surg Oncol 2018;117:1405-12. [DOI: 10.1002/jso.25045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
232 Chen XY, Zhang J, Hou LD, Zhang R, Chen W, Fan HN, Huang YX, Liu H, Zhu JS. Upregulation of PD-L1 predicts poor prognosis and is associated with miR-191-5p dysregulation in colon adenocarcinoma. Int J Immunopathol Pharmacol 2018;32:2058738418790318. [PMID: 30045644 DOI: 10.1177/2058738418790318] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
233 Chen TW, Huang KC, Chiang SF, Chen WT, Ke TW, Chao KSC. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy. J Cancer Res Clin Oncol 2019;145:1043-53. [PMID: 30874889 DOI: 10.1007/s00432-019-02874-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
234 Peng JH, Tai Y, Zhao YX, Luo BJ, Ou QJ, Pan ZZ, Zhang L, Lu ZH. Programmed death-ligand 1 expression in the tumour stroma of colorectal liver oligometastases and its association with prognosis after liver resection. Gastroenterol Rep (Oxf) 2021;9:443-50. [PMID: 34733530 DOI: 10.1093/gastro/goaa077] [Reference Citation Analysis]
235 Jung DH, Park HJ, Jang HH, Kim SH, Jung Y, Lee WS. Clinical Impact of PD-L1 Expression for Survival in Curatively Resected Colon Cancer. Cancer Invest 2020;38:406-14. [PMID: 32762373 DOI: 10.1080/07357907.2020.1793349] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
236 Feng D, Qin B, Pal K, Sun L, Dutta S, Dong H, Liu X, Mukhopadhyay D, Huang S, Sinicrope FA. BRAFV600E-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts. Oncogene 2019;38:6752-66. [PMID: 31406255 DOI: 10.1038/s41388-019-0919-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
237 Li Z, Dong P, Ren M, Song Y, Qian X, Yang Y, Li S, Zhang X, Liu F. PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient. J Cancer. 2016;7:784-793. [PMID: 27162536 DOI: 10.7150/jca.14549] [Cited by in Crossref: 81] [Cited by in F6Publishing: 88] [Article Influence: 13.5] [Reference Citation Analysis]
238 Goltz D, Gevensleben H, Dietrich J, Dietrich D. PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients. Oncoimmunology 2017;6:e1257454. [PMID: 28197377 DOI: 10.1080/2162402X.2016.1257454] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
239 Han J, Hong Y, Lee YS. PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients. J Pathol Transl Med 2017;51:40-8. [PMID: 27989100 DOI: 10.4132/jptm.2016.08.31] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
240 Wu W, Liu Y, Zeng S, Han Y, Shen H. Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes. J Hematol Oncol 2021;14:160. [PMID: 34620200 DOI: 10.1186/s13045-021-01166-3] [Reference Citation Analysis]
241 McMullen KP, Chalmers JJ, Lang JC, Kumar P, Jatana KR. Circulating tumor cells in head and neck cancer: A review. World J Otorhinolaryngol Head Neck Surg 2016;2:109-16. [PMID: 29204555 DOI: 10.1016/j.wjorl.2016.05.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
242 Merelli B, Massi D, Cattaneo L, Mandalà M. Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities. Critical Reviews in Oncology/Hematology 2014;89:140-65. [DOI: 10.1016/j.critrevonc.2013.08.002] [Cited by in Crossref: 100] [Cited by in F6Publishing: 100] [Article Influence: 12.5] [Reference Citation Analysis]
243 Silva MA, Ryall KA, Wilm C, Caldara J, Grote HJ, Patterson-Kane JC. PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters. PLoS One 2018;13:e0196464. [PMID: 29874226 DOI: 10.1371/journal.pone.0196464] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
244 Fan Y, Ma K, Wang C, Ning J, Hu Y, Dong D, Dong X, Geng Q, Li E, Wu Y. Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. Onco Targets Ther. 2016;9:6075-6082. [PMID: 27785054 DOI: 10.2147/ott.s115054] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
245 Siraj AK, Parvathareddy SK, Annaiyappanaidu P, Haqawi W, Al-Rasheed M, AlManea HM, AlHussaini HF, Al-Dayel F, Al-Kuraya KS. PD-L1 Expression Is Associated with Deficient Mismatch Repair and Poor Prognosis in Middle Eastern Colorectal Cancers. J Pers Med 2021;11:73. [PMID: 33530623 DOI: 10.3390/jpm11020073] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
246 Bertucci F, Finetti P, Colpaert C, Mamessier E, Parizel M, Dirix L, Viens P, Birnbaum D, van Laere S. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget 2015;6:13506-19. [PMID: 25940795 DOI: 10.18632/oncotarget.3642] [Cited by in Crossref: 71] [Cited by in F6Publishing: 72] [Article Influence: 11.8] [Reference Citation Analysis]
247 Huang CY, Chiang SF, Ke TW, Chen TW, You YS, Chen WT, Chao KSC. Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II-III colorectal cancer. Sci Rep 2018;8:15658. [PMID: 30353144 DOI: 10.1038/s41598-018-33927-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
248 Yang MW, Fu XL, Jiang YS, Chen XJ, Tao LY, Yang JY, Huo YM, Liu W, Zhang JF, Liu PF, Liu Q, Hua R, Zhang ZG, Sun YW, Liu DJ. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. World J Gastroenterol 2019; 25(14): 1684-1696 [PMID: 31011254 DOI: 10.3748/wjg.v25.i14.1684] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
249 Song F, Jia M, Yu S, Cao L, Sun PL, Gao H. PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma. Histopathology 2021. [PMID: 34156708 DOI: 10.1111/his.14435] [Reference Citation Analysis]
250 Miller TJ, Anyaegbu CC, Lee-Pullen TF, Spalding LJ, Platell CF, McCoy MJ. PD-L1+ dendritic cells in the tumor microenvironment correlate with good prognosis and CD8+ T cell infiltration in colon cancer. Cancer Sci 2021;112:1173-83. [PMID: 33345422 DOI: 10.1111/cas.14781] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
251 Du X, Gao Y, Zhao H, Li B, Xue W, Wang D. Clinicopathological analysis of epithelioid inflammatory myofibroblastic sarcoma. Oncol Lett 2018;15:9317-26. [PMID: 29805657 DOI: 10.3892/ol.2018.8530] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
252 Alexander PG, McMillan DC, Park JH. A meta-analysis of CD274 (PD-L1) assessment and prognosis in colorectal cancer and its role in predicting response to anti-PD-1 therapy. Crit Rev Oncol Hematol 2021;157:103147. [PMID: 33278675 DOI: 10.1016/j.critrevonc.2020.103147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
253 Katsuya Y, Fujita Y, Horinouchi H, Ohe Y, Watanabe S, Tsuta K. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer 2015;88:154-9. [DOI: 10.1016/j.lungcan.2015.03.003] [Cited by in Crossref: 92] [Cited by in F6Publishing: 94] [Article Influence: 13.1] [Reference Citation Analysis]
254 Boustani J, Derangère V, Bertaut A, Adotevi O, Morgand V, Charon-Barra C, Ghiringhelli F, Mirjolet C. Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer. Cells 2020;9:E2071. [PMID: 32927784 DOI: 10.3390/cells9092071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
255 Hirt C, Papadimitropoulos A, Mele V, Muraro MG, Mengus C, Iezzi G, Terracciano L, Martin I, Spagnoli GC. "In vitro" 3D models of tumor-immune system interaction. Adv Drug Deliv Rev 2014;79-80:145-54. [PMID: 24819215 DOI: 10.1016/j.addr.2014.05.003] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 7.4] [Reference Citation Analysis]
256 Fankhauser CD, Curioni-Fontecedro A, Allmann V, Beyer J, Tischler V, Sulser T, Moch H, Bode PK. Frequent PD-L1 expression in testicular germ cell tumors. Br J Cancer 2015;113:411-3. [PMID: 26171934 DOI: 10.1038/bjc.2015.244] [Cited by in Crossref: 89] [Cited by in F6Publishing: 89] [Article Influence: 12.7] [Reference Citation Analysis]
257 Ock CY, Kim S, Keam B, Kim M, Kim TM, Kim JH, Jeon YK, Lee JS, Kwon SK, Hah JH, Kwon TK, Kim DW, Wu HG, Sung MW, Heo DS. PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget 2016;7:15901-14. [PMID: 26893364 DOI: 10.18632/oncotarget.7431] [Cited by in Crossref: 81] [Cited by in F6Publishing: 88] [Article Influence: 16.2] [Reference Citation Analysis]
258 Radvanyi LG. Tumor-Infiltrating Lymphocyte Therapy: Addressing Prevailing Questions. The Cancer Journal 2015;21:450-64. [DOI: 10.1097/ppo.0000000000000162] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
259 Zhang SY, Zhang SQ, Nagaraju GP, El-rayes BF. Biomarkers for personalized medicine in GI cancers. Molecular Aspects of Medicine 2015;45:14-27. [DOI: 10.1016/j.mam.2015.06.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
260 Deng C, Li Z, Guo S, Chen P, Chen X, Zhou Q, Chen J, Yu X, Wu X, Ma W. Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma. Oncoimmunology. 2016;6:e1269047. [PMID: 28344882 DOI: 10.1080/2162402x.2016.1269047] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
261 Cantero-Cid R, Casas-Martin J, Hernández-Jiménez E, Cubillos-Zapata C, Varela-Serrano A, Avendaño-Ortiz J, Casarrubios M, Montalbán-Hernández K, Villacañas-Gil I, Guerra-Pastrián L, Peinado B, Marcano C, Aguirre LA, López-Collazo E. PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells? BMC Cancer 2018;18:945. [PMID: 30285662 DOI: 10.1186/s12885-018-4853-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
262 Kudo M. Immune Checkpoint Blockade in Hepatocellular Carcinoma. Liver Cancer. 2015;4:201-207. [PMID: 26732472 DOI: 10.1159/000367758] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
263 Wang S, Yuan B, Wang Y, Li M, Liu X, Cao J, Li C, Hu J. Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a meta-analysis. Int J Colorectal Dis 2021;36:117-30. [PMID: 32910207 DOI: 10.1007/s00384-020-03734-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
264 Ilcus C, Bagacean C, Tempescul A, Popescu C, Parvu A, Cenariu M, Bocsan C, Zdrenghea M. Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies. Onco Targets Ther 2017;10:2349-63. [PMID: 28496333 DOI: 10.2147/OTT.S133385] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
265 del Rio B, Redruello B, Fernandez M, Martin MC, Ladero V, Alvarez MA. Lactic Acid Bacteria as a Live Delivery System for the in situ Production of Nanobodies in the Human Gastrointestinal Tract. Front Microbiol 2019;9:3179. [DOI: 10.3389/fmicb.2018.03179] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
266 Kudo M. Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update. Liver Cancer. 2016;6:1-12. [PMID: 27995082 DOI: 10.1159/000449342] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 6.5] [Reference Citation Analysis]
267 Kwa M, Adams S. Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in Breast Cancer. Curr Breast Cancer Rep 2016;8:1-13. [DOI: 10.1007/s12609-016-0198-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
268 Toh JWT, de Souza P, Lim SH, Singh P, Chua W, Ng W, Spring KJ. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy. Clin Colorectal Cancer. 2016;15:285-291. [PMID: 27553906 DOI: 10.1016/j.clcc.2016.07.007] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 7.7] [Reference Citation Analysis]
269 Liu J, Liu Y, Wang W, Wang C, Che Y. Expression of immune checkpoint molecules in endometrial carcinoma. Exp Ther Med 2015;10:1947-52. [PMID: 26640578 DOI: 10.3892/etm.2015.2714] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
270 Zheng Y, Yang Y, Wu S, Zhu Y, Tang X, Liu X. Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer. Bioengineered 2017;8:367-73. [PMID: 27754760 DOI: 10.1080/21655979.2016.1230573] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
271 Ni X, Sun X, Wang D, Chen Y, Zhang Y, Li W, Wang L, Suo J. The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis. Clin Transl Oncol 2019;21:674-86. [PMID: 30392153 DOI: 10.1007/s12094-018-1970-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
272 Liu P, Chen R, Zhang X, Fu R, Tao L, Jia W. Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma. BMC Genomics 2022;23. [DOI: 10.1186/s12864-021-08265-y] [Reference Citation Analysis]
273 Frydenlund N, Mahalingam M. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies. Hum Pathol 2017;66:13-33. [PMID: 28694003 DOI: 10.1016/j.humpath.2017.06.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]